FLT3 Inhibitor Quizartinib Improves Survival in AML FLT3 Inhibitor Quizartinib Improves Survival in AML
For the first time, a single agent has produced a survival benefit when compared to standard chemotherapy in a subgroup of patients with relapsed or refractory acute myeloid leukemia.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Health | Hematology | Leukemia